

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215596Orig1s000

PROPRIETARY NAME REVIEW(S)

PROPRIETARY NAME MEMORANDUM

Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	April 21, 2021
Application Type and Number:	NDA 215596
Product Name and Strength:	Livtencity (maribavir) tablet, 200 mg
Product Type:	Single Ingredient Product
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Shire
Panorama or PNR ID #:	2021-1044723884
DMEPA Safety Evaluator:	Melina Fanari, R.Ph.
DMEPA Team Leader:	Sevan Kolejian, PharmD, MBA, BCPPS

1 INTRODUCTION

This memorandum is to reassess the proposed proprietary name, Livtency, which was found conditionally acceptable under IND 051001 on February 18, 2021.^a Thus, Shire submitted the name, Livtency, under NDA 215596 for review on March 23, 2021. We note that all product characteristics remain the same.

2 METHODS AND DISCUSSION

2.1 MISBRANDING ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined that Livtency would not misbrand the proposed product. The Division of Medication Error Prevention and Analysis (DMEPA) and the Division of Antivirals (DAV) concurred with the findings of OPDP's assessment for Livtency.

2.2 SAFETY ASSESSMENT

For re-assessment of the proposed proprietary name, we evaluated the previously identified names of concern considering any lessons learned from recent post-marketing experience, which may have altered our previous conclusion regarding the acceptability of the proposed proprietary name. Our reassessment did not change our conclusion regarding the previously identified names of concern. Additionally, we searched the United States Adopted Name (USAN) stem list to determine if the proposed proprietary name contains any USAN stems as of the last USAN updates. The April 9, 2021 search of USAN stems did not find any USAN stems in the proposed proprietary name, Livtency.

2.3 COMMUNICATION OF DMEPA'S ANALYSIS AT MIDPOINT OF REVIEW

We communicated our findings to the Division of Antivirals (DAV). At that time, we also requested additional information or concerns that could inform our review. On April 20, 2021, the Division of Antivirals (DAV) stated no additional concerns with the proposed proprietary name, Livtency.

3 CONCLUSION

Our re-assessment did not identify any names that represent a potential source of drug name confusion. Therefore, we maintain that the proposed proprietary name, Livtency, is acceptable.

If you have any questions or need clarifications, please contact Mammah Borbor, OSE project manager, at 301-796-7731.

3.1 COMMENTS TO SHIRE

We have completed our review of the proposed proprietary name, Livtency, and have concluded that this name is acceptable.

^a Fanari, Melina. Proprietary Name Review for Livtency (IND 051001). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2021 Feb 18. Panorama No.: 2020-44507200.

If any of the proposed product characteristics as stated in your submission, received on March 23, 2021, are altered prior to approval of the marketing application, the name must be resubmitted for review.

4 REFERENCE

- 1. USAN Stems** (<https://www.ama-assn.org/about/united-states-adopted-names-approved-stems>)

USAN Stems List contains all the recognized USAN stems.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MELINA N FANARI
04/21/2021 08:42:49 AM

SEVAN H KOLEJIAN
04/21/2021 08:46:59 AM